India’s drug regulator has approved Takeda Pharmaceutical's Qdenga, the country’s first vaccine against dengue. The vaccine, which targets all four dengue types, is expected to launch in private markets by early 2027. Takeda has partnered with Biological E to produce up to 50 million doses annually in India to meet the growing demand for disease prevention.
Detailed Coverage
The Central Drugs Standard Control Organization has granted approval to Takeda Pharmaceutical for its dengue vaccine, Qdenga. This marks a milestone in India’s healthcare landscape as the country faces a persistent challenge from seasonal dengue outbreaks. The vaccine is cleared for use in individuals aged four to sixty years and is designed to provide protection against all four known serotypes of the dengue virus.
Clinical Efficacy and Rollout Plans
Clinical data indicates that Qdenga demonstrated 80.2% efficacy against confirmed dengue cases one year after the second dose was administered. Furthermore, the vaccine showed 90.4% efficacy in preventing hospitalizations related to the virus after 18 months of follow-up. For the Indian market, Takeda plans a phased introduction, with availability expected in private healthcare settings during the first half of 2027. The vaccination protocol requires two doses spaced three months apart, and the regulator has cleared it for use regardless of whether an individual has had a prior dengue infection.
Strategic Manufacturing Partnership
Takeda is scaling its global production capabilities with a target of 100 million doses annually by 2030. A key component of this strategy is a partnership with the Indian vaccine manufacturer Biological E, which is expected to support the production of up to 50 million doses per year. This localized production strategy is essential for managing the supply chain and ensuring the vaccine can reach the scale required by India’s large population.
Competitive Landscape and Market Context
The approval comes as public health agencies grapple with rising case counts. Official data shows a significant increase in reported dengue cases over the last twenty years, highlighting the medical need for a preventive solution. While Takeda is the first to receive approval, other companies are also active in this space. Indian Immunologicals Ltd is currently working on its own vaccine candidate and is in the process of conducting clinical trials.
For investors and the public, the primary monitorable will be the pricing strategy for the private market launch in 2027 and the speed at which Takeda and Biological E can establish manufacturing readiness. The success of the rollout will depend on physician adoption and the ability to integrate the vaccine into existing immunization frameworks.